company background image
HZNP

Horizon Therapeutics NasdaqGS:HZNP Stock Report

Last Price

US$104.85

Market Cap

US$23.8b

7D

33.9%

1Y

5.0%

Updated

04 Dec, 2022

Data

Company Financials +
HZNP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance2/6
Financial Health6/6
Dividends0/6

HZNP Stock Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.

Horizon Therapeutics Public Limited Company Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Horizon Therapeutics
Historical stock prices
Current Share PriceUS$104.85
52 Week HighUS$117.49
52 Week LowUS$57.84
Beta1.08
1 Month Change43.77%
3 Month Change74.75%
1 Year Change5.02%
3 Year Change225.32%
5 Year Change603.69%
Change since IPO1,045.90%

Recent News & Updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Recent updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Nov 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Aug 22
Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Aug 04
Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Aug 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon Therapeutics (NASDAQ:HZNP) Has A Rock Solid Balance Sheet

May 20
Horizon Therapeutics (NASDAQ:HZNP) Has A Rock Solid Balance Sheet

Here's Why I Think Horizon Therapeutics (NASDAQ:HZNP) Might Deserve Your Attention Today

May 02
Here's Why I Think Horizon Therapeutics (NASDAQ:HZNP) Might Deserve Your Attention Today

Horizon Therapeutics (NASDAQ:HZNP) Seems To Use Debt Rather Sparingly

Jan 23
Horizon Therapeutics (NASDAQ:HZNP) Seems To Use Debt Rather Sparingly

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Oct 25
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Shares Could Be 42% Below Their Intrinsic Value Estimate

Sep 16
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Shares Could Be 42% Below Their Intrinsic Value Estimate

Shareholder Returns

HZNPUS BiotechsUS Market
7D33.9%4.2%1.5%
1Y5.0%-7.4%-14.9%

Return vs Industry: HZNP exceeded the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: HZNP exceeded the US Market which returned -14.9% over the past year.

Price Volatility

Is HZNP's price volatile compared to industry and market?
HZNP volatility
HZNP Average Weekly Movement9.6%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: HZNP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: HZNP's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20052,095Tim Walberthttps://www.horizontherapeutics.com

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.

Horizon Therapeutics Public Limited Company Fundamentals Summary

How do Horizon Therapeutics's earnings and revenue compare to its market cap?
HZNP fundamental statistics
Market CapUS$23.77b
Earnings (TTM)US$574.26m
Revenue (TTM)US$3.70b

41.4x

P/E Ratio

6.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HZNP income statement (TTM)
RevenueUS$3.70b
Cost of RevenueUS$843.92m
Gross ProfitUS$2.86b
Other ExpensesUS$2.28b
EarningsUS$574.26m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.53
Gross Margin77.20%
Net Profit Margin15.51%
Debt/Equity Ratio51.0%

How did HZNP perform over the long term?

See historical performance and comparison